Rethinking first-line screening in MASLD beyond the limitations of Fibrosis-4 index: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”
Authors:
Open Access
- 1 April 2026
- journal article
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 32 (2) , 921-923
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver diseaseClinical and Molecular Hepatology, 2025
- Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunctionHepatology, 2025
- KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025Clinical and Molecular Hepatology, 2025
- Limited use of FIB‐4 index in patients under 65 years of age with type 2 diabetes mellitusHepatology Research, 2024
- KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver diseaseClinical and Molecular Hepatology, 2024
- Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular diseaseGut, 2023
- Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scoresJournal of Hepatology, 2022
- FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation studyThe Lancet Gastroenterology & Hepatology, 2020